| Title |
Galantamine for Alzheimer's disease and mild cognitive impairment
|
|---|---|
| Published in |
Cochrane database of systematic reviews, January 2006
|
| DOI | 10.1002/14651858.cd001747.pub3 |
| Pubmed ID | |
| Authors |
Clement Loy, Lon Schneider |
| Abstract |
Galantamine is a specific, competitive, and reversible acetylcholinesterase inhibitor. |
X Demographics
The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 17% |
| Spain | 1 | 17% |
| Unknown | 4 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 5 | 83% |
| Practitioners (doctors, other healthcare professionals) | 1 | 17% |
Mendeley readers
The data shown below were compiled from readership statistics for 285 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | <1% |
| United Kingdom | 2 | <1% |
| Brazil | 1 | <1% |
| Ireland | 1 | <1% |
| France | 1 | <1% |
| Belgium | 1 | <1% |
| Singapore | 1 | <1% |
| Japan | 1 | <1% |
| Spain | 1 | <1% |
| Other | 0 | 0% |
| Unknown | 274 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 38 | 13% |
| Student > Bachelor | 33 | 12% |
| Student > Ph. D. Student | 32 | 11% |
| Student > Master | 25 | 9% |
| Other | 21 | 7% |
| Other | 57 | 20% |
| Unknown | 79 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 72 | 25% |
| Psychology | 19 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 18 | 6% |
| Neuroscience | 16 | 6% |
| Biochemistry, Genetics and Molecular Biology | 15 | 5% |
| Other | 61 | 21% |
| Unknown | 84 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 March 2024.
All research outputs
#5,587,368
of 26,017,215 outputs
Outputs from Cochrane database of systematic reviews
#7,802
of 13,168 outputs
Outputs of similar age
#22,583
of 175,299 outputs
Outputs of similar age from Cochrane database of systematic reviews
#25
of 59 outputs
Altmetric has tracked 26,017,215 research outputs across all sources so far. Compared to these this one has done well and is in the 78th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,168 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 35.9. This one is in the 40th percentile – i.e., 40% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 175,299 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 59 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 57% of its contemporaries.